Education
About Us
Working with TipRanks
Follow Us
Surmodics (SRDX)
NASDAQ:SRDX
SRDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.00 - $40.39
Previous CloseN/A
Volume44.36K
Average Volume (3M)178.40K
Market Cap
$416.35M
Enterprise Value$424.14M
Total Cash (Recent Filing)$32.73M
Total Debt (Recent Filing)$32.58M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 05, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding14,297,623
10 Day Avg. Volume142,452
30 Day Avg. Volume178,404
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue3.51
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda-51.54
Forecast
1Y Price Target
$32.00Price Target Upside9.89% Upside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
EarningsSurmodics' Q3 financial results exceeded expectations with revenue and adjusted EPS beating estimates.
Financial GuidanceSurmodics increased its financial guidance for FY/25, reflecting confidence in its future revenue and earnings potential.
Revenue GrowthThrombectomy revenue grew 35%, indicating strong performance in this segment.
Bears Say
Legal ChallengesThe proposed acquisition by GTCR is facing legal challenges due to antitrust concerns from the FTC.
Merger ExpensesMerger-related expenses have been significant, with costs piling up as litigation continues.
Strategic UncertaintyThe ongoing FTC litigation over the GTCR acquisition creates uncertainty for Surmodics' future, potentially impacting its strategic direction.
SurModics News
SRDX FAQ
What was Surmodics’s price range in the past 12 months?
Surmodics lowest stock price was $26.00 and its highest was $40.38 in the past 12 months.
What is Surmodics’s market cap?
Surmodics’s market cap is $416.35M.
When is Surmodics’s upcoming earnings report date?
Surmodics’s upcoming earnings report date is Nov 05, 2025 which is in 30 days.
How were Surmodics’s earnings last quarter?
Surmodics released its earnings results on Jul 30, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.185 by $0.245.
Is Surmodics overvalued?
According to Wall Street analysts Surmodics’s price is currently Undervalued.
Does Surmodics pay dividends?
Surmodics does not currently pay dividends.
What is Surmodics’s EPS estimate?
Surmodics’s EPS estimate is -0.18.
How many shares outstanding does Surmodics have?
Surmodics has 14,297,623 shares outstanding.
What happened to Surmodics’s price movement after its last earnings report?
Surmodics reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.185. Following the earnings report the stock price went up 0.08%.
Which hedge fund is a major shareholder of Surmodics?
Currently, no hedge funds are holding shares in SRDX
SurModics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$32.00 (9.89% Upside)
$32.00 (9.89% Upside)
Blogger Sentiment
Bullish
SRDX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 126.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.76%
12-Months-Change
Fundamentals
Return on Equity
-15.36%
Trailing 12-Months
Asset Growth
-4.28%
Trailing 12-Months
Company Description
Surmodics
SurModics, Inc. (SRDX) is a leading provider of medical device and in vitro diagnostic technologies, primarily serving the healthcare industry. The company specializes in developing innovative coating technologies, drug delivery systems, and biomaterials, which are used in various applications such as cardiovascular, ophthalmology, and other specialty markets. SurModics focuses on enhancing the performance and safety of medical devices through its advanced product offerings and services, aimed at improving patient outcomes.
SRDX Stock 12 Month Forecast
Average Price Target
$32.00
▲(9.89% Upside)
Technical Analysis
Semler Scientific
―
OrthoPediatrics
―
Treace Medical Concepts
―
Cytek Biosciences
―
Ceribell, Inc.
―
Ownership Overview
3.91% Insiders
15.85% Mutual Funds
31.68% Other Institutional Investors
36.89% Public Companies and
Individual Investors